Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

Per Soelberg Sorensen; Jan Lycke; Juha-Pekka Erälinna; Astrid Edland; Xingchen Wu; Jette Lautrup Frederiksen; Annette Oturai; Clas Malmeström; Egon Stenager; Finn Sellebjerg; Helle Bach Sondergaard; SIMCOMBIN study investigators

doi:http://dx.doi.org/10.1016/S1474-4422(11)70144-2

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

Per Soelberg Sorensen, Jan Lycke, Juha-Pekka Erälinna, Astrid Edland, Xingchen Wu, Jette Lautrup Frederiksen, Annette Oturai, Clas Malmeström, Egon Stenager, Finn Sellebjerg, Helle Bach Sondergaard, SIMCOMBIN study investigators

IKM

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

100 Citationer (Scopus)

Abstract

Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.

Originalsprog	Engelsk
Tidsskrift	Lancet Neurology
Vol/bind	10
Udgave nummer	8
Sider (fra-til)	691-701
Antal sider	11
ISSN	1474-4422
DOI	https://doi.org/10.1016/S1474-4422(11)70144-2
Status	Udgivet - 2011

Adgang til dokumentet

http://dx.doi.org/10.1016/S1474-4422(11)70144-2

Citationsformater

Sorensen, P. S., Lycke, J., Erälinna, J-P., Edland, A., Wu, X., Frederiksen, J. L., Oturai, A., Malmeström, C., Stenager, E., Sellebjerg, F., Sondergaard, H. B., & SIMCOMBIN study investigators (2011). Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurology, 10(8), 691-701. https://doi.org/10.1016/S1474-4422(11)70144-2

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. / Sorensen, Per Soelberg; Lycke, Jan; Erälinna, Juha-Pekka; Edland, Astrid; Wu, Xingchen; Frederiksen, Jette Lautrup; Oturai, Annette; Malmeström, Clas; Stenager, Egon; Sellebjerg, Finn; Sondergaard, Helle Bach; SIMCOMBIN study investigators.

I: Lancet Neurology, Bind 10, Nr. 8, 2011, s. 691-701.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Sorensen, PS, Lycke, J, Erälinna, J-P, Edland, A, Wu, X, Frederiksen, JL, Oturai, A, Malmeström, C, Stenager, E, Sellebjerg, F, Sondergaard, HB & SIMCOMBIN study investigators 2011, 'Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial', Lancet Neurology, bind 10, nr. 8, s. 691-701. https://doi.org/10.1016/S1474-4422(11)70144-2

Sorensen, Per Soelberg ; Lycke, Jan ; Erälinna, Juha-Pekka ; Edland, Astrid ; Wu, Xingchen ; Frederiksen, Jette Lautrup ; Oturai, Annette ; Malmeström, Clas ; Stenager, Egon ; Sellebjerg, Finn ; Sondergaard, Helle Bach ; SIMCOMBIN study investigators. / Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. I: Lancet Neurology. 2011 ; Bind 10, Nr. 8. s. 691-701.

@article{cb37e34a44dd4f5eb17a3c236b7aee97,

title = "Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial",

abstract = "Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.",

author = "Sorensen, {Per Soelberg} and Jan Lycke and Juha-Pekka Er{\"a}linna and Astrid Edland and Xingchen Wu and Frederiksen, {Jette Lautrup} and Annette Oturai and Clas Malmestr{\"o}m and Egon Stenager and Finn Sellebjerg and Sondergaard, {Helle Bach} and S{\o}rensen, {Per Soelberg}",

year = "2011",

doi = "http://dx.doi.org/10.1016/S1474-4422(11)70144-2",

language = "English",

volume = "10",

pages = "691--701",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "TheLancet Publishing Group",

number = "8",

}

TY - JOUR

T1 - Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

AU - Sorensen, Per Soelberg

AU - Lycke, Jan

AU - Erälinna, Juha-Pekka

AU - Edland, Astrid

AU - Wu, Xingchen

AU - Frederiksen, Jette Lautrup

AU - Oturai, Annette

AU - Malmeström, Clas

AU - Stenager, Egon

AU - Sellebjerg, Finn

AU - Sondergaard, Helle Bach

AU - SIMCOMBIN study investigators

PY - 2011

Y1 - 2011

N2 - Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.

AB - Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.

U2 - http://dx.doi.org/10.1016/S1474-4422(11)70144-2

DO - http://dx.doi.org/10.1016/S1474-4422(11)70144-2

M3 - Journal article

VL - 10

SP - 691

EP - 701

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 8

ER -